Vera Therapeutics (Nasdaq: VERA) is a late clinical-stage biotechnology company dedicated to developing innovative treatments for serious immunological diseases. With a mission to transform the standard of care for patients, Vera focuses on therapies that target the underlying causes of these diseases. The company's lead product candidate, atacicept, is a self-administered fusion protein designed to block factors that contribute to autoimmune diseases, including IgA nephropathy. In addition to atacicept, Vera is advancing other promising therapies, such as VT-109, a next-generation dual BAFF/APRIL inhibitor, and MAU868, a monoclonal antibody targeting BK virus infections. Committed to a culture of accountability and patient-first values, Vera Therapeutics aims to improve medical treatment for patients suffering from rare diseases.